Overview

Gmax Biopharm LLC. is a clinical stage biopharmaceutical company focusing on G-protein coupled receptors (GPCRs) therapeutic antibody development, to address the unmet medical needs in cardiovascular diseases, metabolic disorders and cancer. Founded in 2010, Gmax has attracted a talent pool of 58 people, with 11 PhDs and MDs, averaging 20 years of extensive biopharmaceutical industry experiences in multinational companies like Amgen, BMS and Genentech. Gmax has established a proprietary world class antibody discovery platform targeting GPCRs. Leveraging this platform, Gmax has built up a pipeline with 9 mAbs targeting 7 different GPCRs for the treatment of diabetes, obesity, PAH, NASH and heart failure. Gmax has also established a unique bispecific antibody platform, Bi-Body. Designed with modular structure, Bi-Body has realized the flexibility of constructing bispecific antibodies, thus engaging T cells to various tumor types. Preliminary data has demonstrated Bi-Body is superior to the BiTE® and CAR-T platforms in stability, PK, immunogenicity and manufacture. Several Bi-Bodies for esophageal cancer and nasopharyngeal cancer are under development.

Leadership Team

Dr. Shuqian Jing

Founder, Chairman and CEO

- Ph.D. of University of California; Zhejiang “Thousand Talents Program”; “China Outstanding Youth Funding”; Professor at Academy of Military Medical Sciences; Professor at Beijing Normal University
- 30 years+ biopharmaceutical industry experiences at Salk Institute, Bristol-Myers Squibb, and Amgen
- Engaged in 20+ drug discovery & development at Amgen
- 40+ publications (5 Cell publications) and 50+ patents

Dr. Cheng Zhang

SVP, CSO

- Ph.D. in Chemistry, UCSD; Zhejiang “Thousand Talents Program”; Visiting Professor of Sichuan University, China
- 30 years+ biopharmaceutical research experiences at MIT, NIH, Millennium Pharmaceuticals and Amgen

Dr. Shun Luo

SVP, COO

- Ph.D. in Biology, University of Virginia; National “Thousand Talents Program”
- Chief process technique supervisor in Amgen and Genentech

Guoqin Pan

CFO

- The Hong Kong University of Finance and Economics MBA; Senior Accountant; CTA
- 20 years+ financial management experience, has served as CFO of several biopharmaceutical companies, and extensive expertise in equity financing

Dr. Kesuo Fan

VP of Pharmaceutical Sciences

- Ph.D. in Biochemistry, University of Massachusetts; Zhejiang “Thousand Talents Program”
- 20 years+ biopharmaceutical R&D experiences at Bristol-Myers Squibb and NIH

Yong Guo

VP of Product Development

- 16 years of new drug R&D experiences
- Major developer of “Conbercept”, the first China innovative antibody drug

Contact us

China

Hangzhou
3F, Building 2,288 Qiuyi Road Binjiang District,Hangzhou, China 310052
Tel: +86-571-86633926
Website: www.gmaxbiopharm.com
Email: info@gmaxbiopharm.com

 

Suzhou

 

Zhengzhou

US

Australia

Gmax Biopharm Australia Pty Ltd 61/41 Rocklands Road
Wollstonecraft NSW 2065 Australia
clinical@gmaxbiopharm.com